Thursday, 23 Jan 2020

You are here

RheumNow Podcast – When You’re Hot You’re Hot (10.11.19)

Dr. Jack Cush delivers select commentary on select news and journal articles from the past week on RheumNow.com.

  1. Just Dx Pigmented Villonodular synovitis in older male w/ CPPD, new myeloma but chronic monarthritis of knee - Dx by MRI. PVNS is benign, localized synovitis (tenosynovitis) of knee, hip, ankle, elbow, even TMJ! Rx is largely excision. https://t.co/R8EHwOaGU4
  2. ASBMR meeting presented a study of patients w/ CKD showing that 12 mos romosuzumab improved BMD in lumbar spine, hip, and femoral neck in pts with mild to moderate renal impairment - not enough pts w/ severe CKD to conclude its effects.
  3. Osteoarthritis Initiative studied 4344 knee OA looking at bulge sign (12.7%) & patellar tap (2%); 3.3% had both. Bulge sign increased risk of freq knee pain (OR 1.31) & TKR [OR 1.47); developing a bulge sign had incr risk of same & Xray worsening (OR 1.67) https://t.co/3HtBrkzAtk 
  4. 225 very early RA in abatacept AVERT study - 44% had high baseline MRI inflammation. With High MRI inflammation, combo ABA+MTX was better than MTX at 12 mos remission by SDAI (45% vs 16%). Pts w/ low baseline MRI inflammation, remission rates did the same https://t.co/A9MRSWaKGB 
  5. Take the Good with the Bad? Study of 179 RA pts achieving remission on TCZ- SC 162 mg qwk randomized to continue qWk or space out to q2Wk -- Weekly Actemra better maintained remission (90% versus 73%; P = 0.004), but then again 73% did well w/ spacing EOW. https://t.co/Tcb2WwCbc2 
  6. Why do we take such crapy care of patients with #gout ? Is it because we have such divergent guidelines? Or we are just overwhelmed?  Your take please..- Sacrilegious but true. Every MD thinks they are great-they learned it in med school & as a PGY*. A) most dont treat enuf to be good at it; b) "guidelines are for suckers"; c) colichicine+allopurinol=Voila! Evidence of bad Rx? no monitoring, underRx, colchicine, 300mg allopur. only   http://bit.ly/2VyeOZi
  7. T2T in Lupus Nephritis aims for less proteinuria, Study of 87 pts with class III/IV LN compared goal of urine protein/creat ratio(UPCR) < 0.5 to stringent < 0.15, Latter assoc w/ lower renal flares (HR  0.16), less CKD (HR 0.19), more MMF use (HR = 7.26) https://t.co/0LSXTiUAaV   
  8. N. Zealand study shows their cost of knee OA was $200 million in 2013; and without any changes in the standards of care, this isprojected to increase to $370 million by 2038. (includes an additional 4,000 TKRs per year by 2038). https://t.co/B1awh1ky1B   
  9. Bisphosphonates and the Risk of Osteonecrosis of the Jaw  
  10. Long Delays for Inflammatory Arthritis Patients   
  11. Antibiotics Increase Rheumatoid Risk - Again  
Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

QD Clinic - "I Don't Know Why I'm Here" Consult

QD Clinic - Lessons from the clinic The Consult that shows up without a cause - and what to do?

CDC: 15% of US Adults are Physically Inactivie

All states and territories had more than 15% of adults who were physically inactive and this estimate ranged from 17.3 to 47.7%,  according to new state maps of adult physical inactivity prevalence released today by the Centers for Disease Control and Prevention (CDC).

RheumNow Podcast- The Down Side of Steroids (1.17.20)

Dr. Jack Cush reviews the journal reports and news from RheumNow.com. Be sure to register for RheumNow Live 3/13/2020 in Fort Worth Rheumnow.live.

RheumNow Podcast- Knee Pain Knockout (1.10.20)

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com. The podcast covers: best therapies for dactylitis and enthesitis; we have a new knockout for knee pain in OA; and are you on the naughty or nice list when it comes to the new ACR-AF guidelines for arthritis? This and more. Tune in.

2019 Rheumatology Year in Review

2019 was a year marked by major advances, hallmark research, and big news items affecting rheumatology.   Herein you will find our top 10 list, formulated by what I think rheumatologists should know and what will likely change their standards and practice in 2020 and beyond.